

# Signe Regner Michaelsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1939274/publications.pdf>

Version: 2024-02-01

39  
papers

977  
citations

516681

16  
h-index

501174

28  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2193  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.   | 16.8 | 376       |
| 2  | Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. <i>BMC Cancer</i> , 2013, 13, 402. | 2.6  | 68        |
| 3  | Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase <scp>KDM</scp>2B. <i>Molecular Oncology</i> , 2018, 12, 406-420.  | 4.6  | 56        |
| 4  | VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. <i>Neuro-Oncology</i> , 2018, 20, 1462-1474.  | 1.2  | 56        |
| 5  | Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 21-32.   | 4.4  | 52        |
| 6  | Assessment of Quantitative and Allelic <i>MGMT</i> Methylation Patterns as a Prognostic Marker in Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 246-255.   | 1.7  | 33        |
| 7  | The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. <i>Cancer Management and Research</i> , 2014, 6, 373.  | 1.9  | 32        |
| 8  | Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1425.  | 2.8  | 30        |
| 9  | Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 272-278.  | 5.0  | 27        |
| 10 | Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. <i>Oncotarget</i> , 2019, 10, 4397-4406.   | 1.8  | 27        |
| 11 | Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors. <i>Neuro-Oncology</i> , 2022, 24, 1074-1087.  | 1.2  | 27        |
| 12 | Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. <i>Molecular Oncology</i> , 2016, 10, 1160-1168.   | 4.6  | 22        |
| 13 | Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. <i>Journal of Neuro-Oncology</i> , 2018, 137, 533-542.  | 2.9  | 19        |
| 14 | DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 679.   | 4.1  | 19        |
| 15 | The Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts. <i>PLoS ONE</i> , 2014, 9, e100009.  | 2.5  | 19        |
| 16 | Single agent and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. <i>Journal of Gene Medicine</i> , 2012, 14, 445-458.                                    | 2.8  | 18        |
| 17 | Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. <i>BMC Cancer</i> , 2017, 17, 278.  | 2.6  | 16        |
| 18 | Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study. <i>Molecular Oncology</i> , 2020, 14, 2727-2743.   | 4.6  | 14        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. <i>Acta Oncologica</i> , 2016, 55, 418-422.   | 1.8  | 11        |
| 20 | Comparison of 18F-FET and 18F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma. <i>Nuclear Medicine and Biology</i> , 2016, 43, 198-205.                    | 0.6  | 10        |
| 21 | A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. <i>Frontiers in Oncology</i> , 2021, 11, 597587. | 2.8  | 10        |
| 22 | 18F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma. <i>PLoS ONE</i> , 2015, 10, e0115315.  | 2.5  | 8         |
| 23 | Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. <i>Cancer Cell International</i> , 2016, 16, 34.      | 4.1  | 8         |
| 24 | Extracranial metastases in glioblastoma—Two case stories. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 289-294.   | 0.5  | 6         |
| 25 | Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. <i>Cancer Investigation</i> , 2018, 36, 165-174.   | 1.3  | 5         |
| 26 | Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2015, 27, 149.  | 16.8 | 3         |
| 27 | Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. <i>Molecular Oncology</i> , 2020, 14, 964-973.  | 4.6  | 2         |
| 28 | VEGF-C as a putative therapeutic target in cancer. <i>Oncotarget</i> , 2019, 10, 3988-3990.   | 1.8  | 2         |
| 29 | Abstract 1369: Inhibition of Notch- and EGFR signaling reduces cell viability and angiogenesis in glioblastoma multiforme. , 2015, , .  |      | 1         |
| 30 | MTR-18PREDICTIVE BIOMARKERS OF BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2015, 17, v128.2-v128.  | 1.2  | 0         |
| 31 | ANGI-15COMBINED TARGETING OF NOTCH AND EGFR DISPLAY ADDITIVE INHIBITORY EFFECTS ON ANGIOGENESIS AND SURVIVAL IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v44.2-v44.  | 1.2  | 0         |
| 32 | DRES-01. ROLE OF HISTONE LYSINE DEMETHYLASE KDM2B IN GLIOBLASTOMA TUMOR CELL MAINTENANCE AND CHEMORESISTANCE. <i>Neuro-Oncology</i> , 2017, 19, vi63-vi64.  | 1.2  | 0         |
| 33 | PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi162-vi163.  | 1.2  | 0         |
| 34 | EPID-13. IDENTIFICATION OF PROGNOSTIC MARKERS IN A COHORT OF CONSECUTIVE NON-SELECTED GLIOBLASTOMA PATIENTS RECEIVING STANDARD THERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi77-vi77.                                      | 1.2  | 0         |
| 35 | PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi149-vi149.  | 1.2  | 0         |
| 36 | RARE-21. CLINICAL CHARACTERISTICS OF GLIOSARCOMA AND OUTCOME FROM STANDARDIZED TREATMENT RELATIVE TO CONVENTIONAL GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi225-vi226.  | 1.2  | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Abstract 4306: A prognostic model for clinical response to bevacizumab in recurrent glioblastoma multiforme. , 2015, , .  |     | 0         |
| 38 | Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients.. Journal of Clinical Oncology, 2018, 36, 2027-2027.  | 1.6 | 0         |
| 39 | Development of a prognostic model for glioblastoma patients treated with standard therapy: A prospective study from a single institution.. Journal of Clinical Oncology, 2018, 36, e14086-e14086. | 1.6 | 0         |